Dren Bio

Executive Summary

Dren Bio is a privately held biopharmaceutical company headquartered in South San Francisco, focused on developing novel therapeutic antibodies for cancer, autoimmune disorders, and other serious diseases. Founded in 2019, the company leverages its proprietary platform to engineer antibodies that selectively engage effector cells for targeted depletion of pathologic cells, protein aggregates, and other disease-causing agents. The management and scientific advisory team bring deep expertise in antibody discovery and engineering, positioning Dren Bio to address significant unmet medical needs. Currently in the pre-clinical stage, the company has not yet disclosed any specific pipeline candidates or raised public capital, but its approach of selective depletion via effector cell engagement could offer advantages over traditional antibody therapies in terms of efficacy and safety.

Upcoming Catalysts (preview)

• Q3 2026Lead Program IND Filing30% success
• 2026Series A or B Financing Announcement50% success
• Q2 2026Presentation of Preclinical Data at Major Conference40% success